(1) Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur. J. Haematol. (2009) 82: 3-7.
(2) Behzad MM, Asnafi AA, Jalalifar MA, Moghtadaei M, Jaseb K and Saki N. Cellular expression of CD markers in immune thrombocytopenic purpura: implications for prognosis. Apmis (2018) 126: 523-32.
(3) Radwan ER and Goda RL. Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of Egyptian childhood immune thrombocytopenic purpura. CATH (2015) 21: 378-82.
(4) Alavi S, Aryan Z, Ghazizadeh F, Arabi N, Nikougoftar M and Ebadi M. The immunophenotype of bone marrow lymphocytes in children with immune thrombocytopenic purpura. Pediatr. Hematol. Oncol. (2014) 31: 548-54.
(5) Stasi R and Newland AC. ITP: a historical perspective. Br. J. Haematol. (2011) 153: 437-50.
(6) Pan J-Q, Wang W, Wang M-L, Li X-Y, Wang JH, Zhao WW, Tian Y-Y, Dong XS and Jiang Y-F. Recognition of the human antibody-mediated platelet destruction in adult ITP patients by C-reactive protein. Int. J. Clin. Exp. Pathol. (2017) 10: 10176–85.
(7) Nazy I, Kelton JG, Moore JC, Clare R, Horsewood P, Smith JW, Ivetic N, D'Souza V, Li N and Arnold DM. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. Br. J. Haematol. (2018) 181: 234-41.
(8) Imbach P and Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N. Engl. J. Med. (2011) 365: 734-41.
(9) Frydman GH, Davis N, Beck PL and Fox JG. Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography. Helicobacter. (2015) 20: 239-51.
(10) Li X, Sheng Z, Sun Y, Wang Y, Xu M, Zhang Z, Li H, Shao L, Zhang Y and Yu J. Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia. Haematologica (2020) 105: 1-47.
(11) Zhang HW, Zhou P, Wang K-Z, Liu J-B, Huang Y-S, Tu Y-T, Deng ZH, Zhu XD and Hang YL. Platelet proteomics in diagnostic differentiation of primary immune thrombocytopenia using SELDI-TOF-MS. Clinica. Chimica. Acta (2016) 455: 75-79.
(12) Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB and Godeau B. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. Am. J. Hematol. (2010) 115: 168-86.
(13) Samson M, Fraser W and Lebowitz D. Treatments for Primary Immune Thrombocytopenia: A Review. Cureus. (2019) 11: e5849.
(14) Zainal A, Salama A and Alweis R. Immune thrombocytopenic purpura. J. Community Hosp. Intern. Med. Perspect. (2019) 9: 59-61.
(15) Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, Pabinger I and Rummel M. Immune thrombocytopenia-current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol. Res. Treat (2018) 41: 1-30.
(16) Neunert CE. Current management of immune thrombocytopenia, Hematology (2013) 2013: 276-82.
(17) Quackenbush J. Computational analysis of microarray data. Nat. Rev. Genet. (2001) 2: 418-27.
(18) Butte A. The use and analysis of microarray data. Nat. Rev. Drug Discov. (2002) 1: 951-60.
(19) Arrell D and Terzic A.. Network systems biology for drug discovery. Clin Pharmacol Ther. (2010) 88: 120-5.
(20) Penrod NM, Cowper-Sal lari R and Moore JH. Systems genetics for drug target discovery. Trends Pharmacol. Sci. (2011) 32: 623-30.
(21) Jernås M, Hou Y, Strömberg Célind F, Shao L, Nookaew I, Wang Q, Ju X, Mellgren K, Wadenvik H and Hou M. Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP. Blood Am. J. Hematol. (2013) 122: 1789-92.
(22) Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. (2009) 4: 44-57.
(23) Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky Lazareva B, Muruganujan A and Rabkin S. Muruganujan and S. Rabkin, PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. (2003) 31: 334-41.
(24) Sun RJ and Shan NN. Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. Cancer Cell Int. (2019) 19: 59-69.
(25) Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist (2009) 14: 12-21.
(26) Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB and Gunnarsdottir S. Genetics of gene expression and its effect on disease. Nature (2008) 452: 423-8.
(27) Liang M, Cowley Jr AW and Greene AS. High throughput gene expression profiling: a molecular approach to integrative physiology. J. Physiol. (2004) 554: 22-30.
(28) Wang CY, Ma S, Bi SJ, Su L, Huang S-Y, Miao J-Y, Ma CH, Gao C-J and Hou M, Peng J, Enhancing autophagy protects platelets in immune thrombocytopenia patients. Ann. Transl. Med. (2019) 7: 8-18.
(29) Shan N-n, Dong Ll, Zhang X-m, Liu X and Li Y. Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapy. Crit. Rev. Oncol. Hematol. (2016) 100: 11-5.
(30) Liu Z and Mei T. Immune thrombocytopenia induces autophagy and suppresses apoptosis in megakaryocytes. Mol. Med. Rep. (2018) 18: 4016-22.
(31) Schwanbeck R and Just U. The Notch signaling pathway in hematopoiesis and hematologic malignancies. haematologica (2011) 96: 1735-7.
(32) Gawdat RM, Hammam AA and Ezzat DA. Correlation of Notch1/Hes1 Genes Expression Levels in Egyptian Paediatric Patients with Newly Diagnosed and Persistent Primary Immune (Idiopathic) Thrombocytopenic Purpura. Indian J. Hematol. Blood Transfus. (2016) 32: 362-7.
(33) Ma D, Zhu Y, Ji C and Hou M. Hou. Targeting the Notch signaling pathway in autoimmune diseases. Expert Opin. Ther. Targets (2010) 14: 553-65.
(34) Rigby RE and Rehwinkel J. RNA degradation in antiviral immunity and autoimmunity. Trends. Immunol. (2015) 36: 179-88.
(35) Dellagi K, Vainchenker W, Vinci G, Paulin D and Brouet JC. Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells. EMBO. J. (1983) 2: 1509-14.
(36) Beneš P, Macečková V, Zdráhal Z, Konečná H, Zahradníčková E, Mužík J and Šmarda J. Role of vimentin in regulation of monocyte/macrophage differentiation. Differentiation (2006) 74: 265-76.
(37) Pleines I, Cherpokova D and Bender M. Rho GTPases and their downstream effectors in megakaryocyte biology. Platelets (2019) 30: 9-16.
(38) Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato Otsubo A, Kon A and Nagasaki M. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 478: 64-69.
(39) Suo Z, Cox AA, Bartelli N, Rasul I, Festoff BW, Premont RT and Arendash GW. GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiol. Aging (2007) 28: 1873-88.
(40) Wang L, Shen M, Wang F and Ma L.GRK5 ablation contributes to insulin resistance. Biochem. Biophys. Res. Commun. (2012) 429: 99-104.
(41) Islam KN, Bae JW, Gao E and Koch WJ. Regulation of nuclear factor κB (NF-κB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5). J. Biol. Chem. (2013) 288: 35683-9.
(42) Chakraborty PK, Zhang Y, Coomes AS, Kim WJ, Stupay R, Lynch LD, Atkinson T, Kim JI, Nie Z and Daaka Y. G Protein–Coupled Receptor Kinase GRK5 Phosphorylates Moesin and Regulates Metastasis in Prostate Cancer. Cancer Res. (2014) 74: 3489-500.
(43) Kaur G, Kim J, Kaur R, Tan I, Bloch O, Sun MZ, Safaee M, Oh MC, Sughrue M and Phillips J. G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. J. Clin. Neurosci. (2013) 20: 1014-8.
(44) Kim JI, Chakraborty P, Wang Z and Daaka Y. G-protein coupled receptor kinase 5 regulates prostate tumor growth. J. Urol. (2012) 187: 322-9.
(45) O'Neill LA, Bryant CE and Doyle S. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. (2009) 61: 177-97.
(46) Packiriswamy N, Parvataneni S and Parameswaran N. Overlapping and distinct roles of GRK5 in TLR2-, and TLR3-induced inflammatory response in-vivo, Cell. Immunol. (2012) 272: 107-11.
(47) Delaney A and Yoganathan T. G protein coupled receptor kinase 5 (GRK5) and its uses, Google Patents. (2002) 649: 1-16.
(48) Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE and Mueller W. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer—association with tumour cell proliferation. J. Pathol. (2003) 200: 16-22.
(49) Sudakin V, Chan GK and Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J. Cell Biol. (2001) 154: 925-36.
(50) de Voer RM, van Kessel AG, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede L, Kamping EJ, Verwiel ET and Hahn MM. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. Gastroenterology (2013) 145: 544-7.
(51) Mukherjee A, Joseph C, Craze M, Chrysanthou E and Ellis IO. The role of BUB and CDC proteins in low-grade breast cancers. Lancet (2015) 385: S72.
(52) Schneider MV and Orchard S. Omics technologies, data and bioinformatics principles, Bioinformatics for omics Data. Springer (2011) 3-30.